Amylyx Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(6.8%),TCG Crossover Fund II, L.P.(6.8%), etc.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.